Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00373659 · ClinicalTrials.gov registry record · Phase 2
An OCT-Guided Variable Dosing Regimen With Ranibizumab for the Treatment of Neovascular AMD
A Phase 2 study, sponsored by University of Miami.
- Completed
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
NCT00373659 is a Phase 2 study that has completed, run by University of Miami. The registered enrollment target is 40 participants.
The verdict
NCT00373659, a Phase 2 study, has completed, sponsored by University of Miami.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
Study Summary
This study was designed to evaluate a variable dosing regimen with intravitreal ranibizumab for the treatment of patients with neovascular age-related macular degeneration (AMD) in the Prospective OCT Imaging of Patients with Neovascular AMD Treated with Intra-Ocular Ranibizumab (PrONTO) study.
Interventions
- DRUG Ranibizumab (Lucentis)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2004-08 |
| Est. Completion | 2007-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00373659
The ClinicalTrials.gov registry entry for NCT00373659 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Miami, which has 721 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Ranibizumab (Lucentis) is the first listed.
NCT00373659 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00373659 about?
NCT00373659 is a clinical study titled "An OCT-Guided Variable Dosing Regimen With Ranibizumab for the Treatment of Neovascular AMD". This study was designed to evaluate a variable dosing regimen with intravitreal ranibizumab for the treatment of patients with neovascular age-related macular degeneration (AMD) in the Prospective OCT Imaging of Patients with Neovascular AMD Treated with Intra-Ocular Ranibizumab (PrONTO) study.
What is the current status of trial NCT00373659?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2004-08. Estimated completion is 2007-06.
What interventions are being tested in trial NCT00373659?
The interventions under investigation include: Ranibizumab (Lucentis) (DRUG).
Who is sponsoring clinical trial NCT00373659?
This trial is sponsored by University of Miami, which has 721 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.